Summary In this session, Nir Barzilai, professor at Albert Einstein School of Medicine and director of Institute for Aging Research, presented the current state of the groundbreaking TAME trial serving as a framework and data springboard for the whole longevity field, as well as the future plans for other TAME-like trials with other drugs with… Continue reading TAME Q&A: Lessons for Progress on Aging | Nir Barzilai, Albert Einstein School of Medicine
Summary In this session, Keith Murphy, founder of Organovo and CEO and founder of Viscient Biosciences, covered the recent developments in the field of 3D tissue bioprinting and human organ models on a chip or sometimes also called patient trials in a dish. He went into the different technologies that are being used and trialed,… Continue reading ”Patient Trials in a Dish” Paths Forward | David Gobel, Methuselah, Keith Murphy, Organovo
Summary In this session, Morgan Levine, Assistant Professor at Yale, gave a sneak peek into the new epigenetic clock they are developing that is able to probe into multiple organ systems, as well as on a new approach how to calculate clocks that is much more reliable, enabling to generate insights from methylation clocks with… Continue reading Biomarker Standardization | Morgan Levine, Yale, Jamie Justice, Wake Forest School of Medicine
Summary In this session, Steve Horvath, professor at the University of California Los Angeles, provided an overview of the current state of the epigenetic clock field and the new developments in it. Then he went on to talk about what is missing in regards to methylation clocks and the longevity field itself, as well as… Continue reading EpigeneticClocks: What’s New & What’s Missing? | Steve Horvath, UCLA
Summary In this session, Gordan Lauc (Genos Glyco & GlycanAge) and Vadim Gladyshev (Harvard), gave their point of view on biomarkers & aging clocks development. Gordan Lauc went through the interesting glycomic data they recently and insights it generated about aging and menopause, exceptional predictive capability of glycans for hypertension, and much more. Vadim Gladyshev… Continue reading Biomarker & Aging Clock Development | Vadim Gladyshev, Harvard, Gordan Lauc, GlycanAge
Summary In this session, Alex Zhavoronkov, CEO and Founder of Insilico Medicine and Deep Longevity, offered his roadmap for what he calls Longevity as a Service. He explained the approach Deep Longevity and Young.ai are taking, the various clocks and machine learning methods they are using, the necessity for physician education and coordinated building of… Continue reading Longevity as a Service: AI & Aging Clocks | Alex Zhavoronkov, Deep Longevity & Insilico Medicine
Summary In this session, Dylan Livingston, Founder and Executive Director at The Alliance for Longevity Initiatives, introduced the first 501(c)(4) nonprofit organization focused on advocating for government-sponsored initiatives and policies to increase healthy human lifespan in the US. He went over the reasons why it was needed and teased the first draft of the action… Continue reading Dylan Livingston | ALARMA (America’s Longevity, Aging and Regenerative Medicine Association)
Summary In this session, Greg Fahy, Co-Founder of Intervene Immune and Principal Investigator of the TRIIM and TRIIM-X clinical trials, offered a sneak peek on some preliminary data from the TRIIM-X clinical trial along with updates about its development, progress and conditions of the enrollment, as well as optimistically looking first preliminary results. Following discussion… Continue reading Greg Fahy, Intervene Immune | Thymus Rejuvenation Progress Update
Summary In this session, Christopher Leptak, the Director New Drug’s Regulatory Science Program Office in the FDA’s Center for Drug Evaluation and Research, elucidated how is FDA approaching biomarkers specifically for drug development, what is actually considered a biomarker and wha needs to happen for a new biomarker to be used. Apart from valuable tips… Continue reading Biomarkers and Drug Development: Regulatory Perspective | Christopher Leptak
Summary In this session, James Peyer, the CEO and founder of Cambrian Biopharma, shared his overview of the longevity biotech industry with insights into what it actually means to be a longevity biotech company, how Cambrian functions, what is a DisCo model and why it will most likely replace single asset biotech companies model, and… Continue reading James Peyer | Cambrian Bio: How to Fund and Build Geroprotectors
